Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation

Manuel Rodríguez-Perálvarez,Marta Guerrero,L Barrera,Gustavo Ferrín,J.M. Álamo,M.D. Ayllón,Gonzalo Suárez Artacho,J.L. Montero,Javier Briceño,C. Bernal,Javier Padillo,Luis Miguel Marín-Gómez,J.M. Pascasio,Antonio Poyato,Miguel Ángel Gómez-Bravo,Manuel de la Mata

Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation

2018

Manuel Rodríguez-Perálvarez
Marta Guerrero
L Barrera
Gustavo Ferrín
J.M. Álamo
M.D. Ayllón
Gonzalo Suárez Artacho
J.L. Montero
Javier Briceño
C. Bernal
Javier Padillo
Luis Miguel Marín-Gómez
J.M. Pascasio
Antonio Poyato
Miguel Ángel Gómez-Bravo
Manuel de la Mata

BackgroundMany centers implement everolimus-based immunosuppression in liver transplant patients with hepatocellular carcinoma. We aimed to explore the potential impact of early initiated everolimus on tumor recurrence after liver transplantation.MethodsThis study included 192 patients with hepatoce

Keywords:

Immunology
Hepatocellular carcinoma
Diabetes mellitus
Cancer research
Liver transplantation
Everolimus
Medicine
Prospective cohort study
Immunosuppression
Progression-free survival
Oncology
Internal medicine
Case-control study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations